90% response to cancer vaccine

(Thanks to NoCamels.com) Julian Levy, CFO of Israel’s Vaxil Biotherapeutics speaks to NoCamels about Vaxil’s cancer vaccine, ImMucin, that boosts the immune system and prevents cancer returning.  ImMucin triggers a response in about 90 percent of all types of cancer.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *